EAM
FATE icon

EFG Asset Management’s Fate Therapeutics FATE Stock Holding History

EFG Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-68,082
Closed -$1.53M – 175
2022
Q3 		$1.53M Buy
68,082
+21,527
+46% +$622K 0.35% 102
2022
Q2 		$1.15M Sell
46,555
-109,902
-70% -$3.03M 0.24% 129
2022
Q1 		$6.07M Buy
156,457
+27,261
+21% +$1.06M 0.91% 39
2021
Q4 		$7.57M Buy
+129,196
New +$7.32M 0.99% 36

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EFG Asset Management's FATE Position: Q4 2022 in Review

EFG Asset Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 68,082 shares — an estimated $1.53M sold.

EFG Asset Management first reported a position in FATE in Q4 2021 and held it in 4 quarters. The position peaked at $7.57M in Q4 2021. 228 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • EFG Asset Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EFG Asset Management sold 68,082 Fate Therapeutics shares in Q4 2022, an estimated $1.53M.
  • EFG Asset Management first reported a position in Fate Therapeutics in Q4 2021 and held it in 4 quarters.
  • EFG Asset Management's Fate Therapeutics position peaked at $7.57M in Q4 2021.
  • 228 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on EFG Asset Management's 13F filing for Q4 2022, filed 3 Feb 2023.